Here, our high-throughput screening reveals that Silmitasertib, a clinically used Casein Kinase II inhibitor, leads to more than 90% decrease of YAP1 protein level and potently suppresses YAP1-driven ovarian cancer progression. Here, YAP1 is linked to ovarian carcinoma.